Why you should be reading the Tariff Tracker – a leading SR indicator

We publish monthly front book pricing data in our Tariff Tracker product. In this report we show some new analysis looking at how front book tariffs are a good leading indicator for service revenue trends in mobile and fixed, including new work looking at discounted and undiscounted prices.

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 2,350 shares at 349.044DKK and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Telia Company AB: 1 director

A director at Telia Company AB bought 35,000 shares at 35.020SEK and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

EU Telecoms: Half-time 2025 Review Sector has outperformed: More sele...

The European Telecoms continues to outperform: up 17% YTD vs. the market up 10%. While this is great to see, adding to the 12pp outperformance in 2024 and supporting our investment thesis of improving regulation, it does mean the equity upside story from here is becoming more selective.

Telia performs well/Bredband2 acquisition doesn't come cheap

Telia reported solid 2Q25 results which were in line with expectations. However, the most interesting news was its bid for Bredband2, a large Swedish provider of broadband services. Although we think the intended acquisition comes somewhat expensive, we like the potential improvement of Telia's broadband market share to c.41.5% in Sweden. Regulatory approval for the transaction is very well possible when comparing Sweden with other European countries. Telia's credit profile continues to look sou...

Telia (Buy from Neutral, TP: SEK 40, +15%) OpEx execution (& M&A) lif...

It has been a busy few days for Telia: it reported a good set of Q2 results last week and announced a deal to sell its Latvian business and a deal to buy Swedish fibre provider Bredband2. We look at these events in this report, and upgrade Telia to a Buy.

Not enough to excite us

Small cost driven beat

Headwinds entering in Q2e

Trends continue, valuation not too appealing

Expert speaker call: latent market share gains

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

Telia Company (Buy, TP: SEK39.00) - On track towards full-year targets

Telia reported a solid Q1, with 1.8% service revenue growth YOY, 6.7% EBITDA growth, and SEK1.7bn in FCF. The performance strengthens our view that Telia can reach its full-year targets. We reiterate our BUY and have raised our target price to SEK39 (38.5).

Good Q1, but heading for deceleration

Telia (Neutral, TP: SEK 37, +5%) Q1 25: Impressive EBITDA acceleratio...

Telia has reported a good set of results, with SR, EBITDA, capex and all-in FCF all better than consensus expectations. The company sounded a note of caution on the call that Q1 Group trends were better than we should expect for the full year; having EBITDA and FCF in the bag already is a good thing, but full year guidance has been reiterated not raised.

Small adj. EBITDA beat, unchanged guidance

Heads-up for report 24 April